US HR161 | 2013-2014 | 113th Congress

Status

Spectrum: Bipartisan Bill
Status: Introduced on April 15 2013 - 25% progression, died in committee
Action: 2013-04-19 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]

Summary

Expresses the sense of the House of Representatives that the Food and Drug Administration (FDA) should exercise its acknowledged authority to: (1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations, and (2) require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Expressing the sense of the House of Representatives that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.

Sponsors


History

DateChamberAction
2013-04-19HouseReferred to the Subcommittee on Health.
2013-04-15HouseReferred to the House Committee on Energy and Commerce.

Same As/Similar To

SR97 (Related) 2013-04-15 - Referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S2654)

Subjects


US Congress State Sources


Bill Comments

feedback